As previously announced, Aegirbio AB has received a phase 1 award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program for an accessibility project.

During the finalisation of the terms the parties have agreed on atimeline and resources. The award grants Aegirbio $1.2 million from the NIH RADx® Tech program, which is administered by the National Institute of Biomedical Imaging and Bioengineering. 

This allocation is designated for the development of a digital multiplex self-test platform, with the purpose of providing vital assistance to individuals with disabilities. The initial award has the potential for phase 2 funding pending successful completion of phase 1.

CEO Marco Witteveen commented: “We are honoured and enthusiastic to have been chosen to participate in this program. This marks a significant milestone for Aegirbio AB, serving as a tangible external validation of our emerging saliva testing platform. This accomplishment is entirely aligned with our core mission - the advancement of accessible biomarker assay technologies. These innovations are designed to empower individuals by enabling them to monitor their health and enhance their treatment outcomes. It reinforces our broader commitment to providing an integrated, user-friendly diagnostic and monitoring platform, empowering individuals to take charge of their health through non-invasive testing.”

This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | info@eminova.se

Related link:
Cision